Immune Responses against SARS-CoV-2 Variants after Two and Three Doses of Vaccine in B-cell Malignancies: UK PROSECO Study

The authors presented the PROSECO prospective observational study on 457 patients with lymphoma that received two or three COVID-19 vaccine doses and showed undetectable humoral responses following two vaccine doses in 52% of patients undergoing active anticancer treatment.